LOUISVILLE, Colo., April 29 /PRNewswire-FirstCall/ -- Replidyne, Inc.
(Nasdaq: RDYN) announced today that it will hold a conference call on
Wednesday, May 7, 2008 at 4:45 P.M. ET to report first quarter 2008
earnings. On Thursday, May 8, 2008 at 4:00 P.M. ET Replidyne will host its
annual shareholder meeting at Company headquarters at 1450 Infinite Drive
in Louisville, CO.
Earnings conference call information is as follows:
Kenneth J. Collins, President and CEO, and other members of Replidyne's
management team will discuss earnings results via conference call and
webcast on Wednesday, May 7, 2008, at 4:45 P.M. ET. Callers may
participate in the conference call by dialing 866-770-7125 (domestic) or
617-213-8066 (international), and providing the passcode 79991920. To
access the live webcast, please log on to the Company's website at
http://www.Replidyne.com and go to the Investor Relations section.
A replay of the conference call will be available approximately one hour
after completion of the call through Wednesday, May 21, 2008 at
midnight. Callers may access the replay by dialing 888-286-8010 (U.S.
participants) or 617-801-6888 (international participants). The audio
replay passcode is 81984297. To access a replay of the webcast, visit
the Investor Relations section of the Company's website at
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's most advanced product candidate, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile Infection (CDI). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.
This press release contains plans, intentions, objectives, estimates and expectations that constitute forward-looking statements about Replidyne, Inc. that involve significant risks and uncertainties. Actual results could differ materially from those discussed due to a number of factors including, the success and timing of pre-clinical studies and clinical trials; the Company's ability to obtain a new partner for faropenem on acceptable terms; the Company's ability to obtain and maintain regulatory approval of product candidates and the labeling under any approval that may be obtained; plans to develop and commercialize product candidates; the loss of key scientific or management personnel; the size and growth of the potential markets for the Company's product candidates and the Company's ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of Company estimates regarding expenses, future revenues and capital requirements; the Company's ability to obtain and maintain intellectual property protection for our product candidates; the successful development of the Company's sales and marketing capabilities; the success of competing drugs that are or become available; and the performance of third party manufacturers. These and additional risks and uncertainties are described more fully in the Company's most recent Form 10-K filed with the SEC under the Securities Exchange Act of 1934. Copies of filings made with the SEC are available through the SEC's electronic data gathering analysis and retrieval system (EDGAR) at http://www.sec.gov. All forward-looking statements made in the press release are made as of the date hereof and the Company assumes no obligation to update the forward-looking statements in the document.
|SOURCE Replidyne, Inc.|
Copyright©2008 PR Newswire.
All rights reserved